Living with Parkinson's disease involves facing complex challenges like muscle and movement issues. Researchers are now looking closely at GLP-1 receptor agonists to see if these drugs can help manage the condition by addressing underlying problems like insulin resistance and inflammation.
A review of 282 articles shows that scientists are focusing on specific areas, such as how these drugs affect the blood-brain barrier and oxidative stress. They are also looking into new combinations, like GIP/GLP-1 dual agonists, to see if they can better protect brain health and manage mild cognitive impairment.
It is important to note that this study was a review of existing research papers rather than a clinical trial on patients. Because the drugs vary so much and the studies used different groups of people, the current evidence is still inconsistent. More research is needed to see how these treatments work in real-world practice.
